Clinical Trial Update: Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial assessing the combination of pasireotide and RAD001 (everolimus) in patients with advanced neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Pasireotide (pasireotide)
• RAD001 (Everolimus) (everolimus)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Neuroendocrine Tumor, Carcinoid Tumor | Phase 1 | Status: COMPLETED